From October 2025: AI, imaging, and devices are part of the core enabling capabilities of Roche’s ophthalmology strategy. The company is thus not just aiming to sell current treatments, but to manage the entire vision loss pathway from early detection to restorative treatments in later stages. This is a broad strategic framework into which AI imaging fits well. Hmm… getting warmer, getting warmer…
19 Likes